Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

NCT07020065 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Metastatic NSCLC - Non-Small Cell Lung Cancer

Interventions

DRUG: Cemiplimab
DRUG: Carboplatin
DRUG: Pemetrexed & Gemcitabine
DRUG: Paclitaxel

Sponsor

Swiss Cancer Institute